1. Home
  2. ARDX vs MNKD Comparison

ARDX vs MNKD Comparison

Compare ARDX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$7.99

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$5.93

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARDX
MNKD
Founded
2007
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2014
2004

Fundamental Metrics

Financial Performance
Metric
ARDX
MNKD
Price
$7.99
$5.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
6
Target Price
$12.95
$10.08
AVG Volume (30 Days)
6.3M
3.5M
Earning Date
02-19-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.47
EPS
N/A
0.10
Revenue
$398,234,000.00
$313,787,000.00
Revenue This Year
$22.65
$21.40
Revenue Next Year
$31.33
$25.03
P/E Ratio
N/A
$58.33
Revenue Growth
58.12
17.43
52 Week Low
$3.21
$3.38
52 Week High
$8.17
$6.51

Technical Indicators

Market Signals
Indicator
ARDX
MNKD
Relative Strength Index (RSI) 66.23 57.24
Support Level $6.73 $5.03
Resistance Level $7.25 $5.68
Average True Range (ATR) 0.57 0.27
MACD 0.14 -0.01
Stochastic Oscillator 89.03 59.80

Price Performance

Historical Comparison
ARDX
MNKD

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Share on Social Networks: